Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -87.25
- Piotroski Score 4.00
- Grade Buy
- Symbol (BIOR)
- Company Biora Therapeutics, Inc.
- Price $0.57
- Changes Percentage (9.13%)
- Change $0.05
- Day Low $0.53
- Day High $0.59
- Year High $2.71
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.43
- Trailing P/E Ratio -0.11
- Forward P/E Ratio -0.11
- P/E Growth -0.11
- Net Income $-124,115,000
Income Statement
Quarterly
Annual
Latest News of BIOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
PROCEPT BioRobotics Corporation (PRCT) Advances Urology with AI-Integrated HYDROS Robotic System; Price Target Raised to $99
PROCEPT BioRobotics Corporation is a surgical robotics company with an AI-integrated system for urology. Despite its potential, other AI stocks may offer higher returns in a shorter timeframe. Check o...
By Yahoo! Finance | 21 hours ago -
Jim Cramer Prefers Intuitive Surgical, Inc. (NASDAQ:ISRG) Over Procept Biorobotics
A recent list of Jim Cramer Stock Portfolio for Q4 highlights Intuitive Surgical, Inc. as a top choice. Cramer advises taking profits during stock rallies and recommends ISRG over Procept Biorobotics....
By Yahoo! Finance | 1 week ago -
Procept Biorobotics Corporation (PRCT): Why Are Short Sellers Betting Against This Hospital Tech Innovator?
PROCEPT BioRobotics Corp. (NASDAQ: PRCT) was analyzed against other worst small cap AI stocks. The recent interest rate cut by the Fed aimed at stabilizing the labor market....
By Yahoo! Finance | 1 week ago
